Bioventus Inc. ( BVS ) Q3 2025 Earnings Call November 4, 2025 8:30 AM EST Company Participants David Crawford - Vice President of Investor Relations & Treasurer Robert Claypoole - President, CEO & Director Mark Singleton - Senior VP & CFO Conference Call Participants Chase Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Ross Osborn - Cantor Fitzgerald & Co., Research Division Caitlin Cronin - Canaccord Genuity Corp., Research Division Presentation Operator Good day, and welcome to the Bioventus Inc. Third Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded.
Bioventus Inc. (NASDAQ:BVS ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 1:05 PM EDT Company Participants Mark Singleton - Senior VP & CFO Presentation Unknown Analyst Thanks, everyone, for joining us. Before we begin, just the disclaimer.
Bioventus Inc. (NASDAQ:BVS ) Q2 2025 Earnings Conference Call August 6, 2025 8:30 AM ET Company Participants David Crawford - Vice President of Investor Relations & Treasurer Mark L. Singleton - Senior VP & CFO Robert E.
Bioventus (BVS) came out with quarterly earnings of $0.21 per share, missing the Zacks Consensus Estimate of $0.22 per share. This compares to earnings of $0.19 per share a year ago.
Bioventus Inc. (NASDAQ:BVS ) Q1 2025 Results Conference Call May 6, 2025 8:30 AM ET Company Participants Dave Crawford - Investor Relations Rob Claypoole - President & Chief Executive Officer Mark Singleton - Senior Vice President & Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig Hallum Robbie Marcus - JPMorgan Operator Good day, and welcome to the Bioventus First Quarter 2025 Conference Call. [Operator Instructions] Please note this event is being recorded.
Bioventus (BVS) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.07 per share a year ago.
Buy healthcare stocks like WGS, THC, RIGL and ENSG for steady returns as the focus shifts to the Trump administration's healthcare policies.
Bioventus (BVS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Bioventus (BVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Bioventus Inc. (NASDAQ:BVS ) Q4 2024 Earnings Conference Call March 11, 2025 8:30 AM ET Company Participants Dave Crawford - Investor Relations Rob Claypoole - President & Chief Executive Officer Mark Singleton - Senior Vice President & Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Caitlin Cronin - Canaccord Genuity Operator Good morning and welcome to the Bioventus Fourth Quarter 2024 Earnings Conference Call. All participants will be in listen-only mode.
On Tuesday, Bioventus Inc. BVS reported fourth-quarter adjusted EPS of 15 cents, up from 7 cents, beating the consensus of 8 cents.
Bioventus (BVS) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.07 per share a year ago.